Biotechnology

Ocugen

Ocugen released FY2026 Q1 earnings on May 5 Pre-Market EST, actual revenue USD 1.533 M (forecast USD 450 K), actual EPS USD -0.0599 (forecast USD -0.0516)

Ocugen to Release FY2026 Q1 Earnings on May 5 Pre-Market EST, Forecast Revenue USD 358.14 K, EPS USD -0.0514

Ocugen Completes OCU410ST Gene Therapy Dosing for Stargardt Disease Phase 2/3 Clinical Trial

Ocugen to Hold Webcast Discussing Clinical Trial Data for Gene Therapy

Ocugen released FY2025 Q4 earnings on March 4 Pre-Market (EST), actual revenue USD -193 K (forecast USD 860 K), actual EPS USD -0.0566 (forecast USD -0.058)

Ocugen released FY2025 Annual Earnings on March 4 Pre-Market (EST), actual revenue USD 4.413 M (forecast USD 5.402 M), actual EPS USD -0.226 (forecast USD -0.228)

Ocugen to Release FY2025 Q4 Earnings on March 4, 2026 Pre-Market EST, Forecast Revenue USD 860K, EPS USD -0.058

Ocugen Inc to Issue 15 Million Ordinary Shares With Expected Proceeds of $22.5 Million

Ocugen Announces Positive Data for Gene Therapy in Dry Age-Related Macular Degeneration

H.C. Wainwright Analyst Reiterates Buy Rating on Ocugen

Ocugen released FY2025 Q3 earnings on November 5 Pre-Market EST, actual revenue USD 1.752 M (forecast USD 440 K), actual EPS USD -0.0699 (forecast USD -0.056)

Ocugen released FY2025 9 Months Earnings on November 5, Pre-Market EST, with actual revenue of USD 4.606 M and EPS of USD -0.1689

Ocugen Inc. Reports Clinical Trial Progress and Completes $20 Million Direct Offering

Ocugen to Release FY2025 Q3 Earnings on November 5, Pre-Market EST; Forecast Revenue USD 440 K, EPS USD -0.056

Ocugen Executives to Attend Multiple Conferences to Share Progress in Blindness Gene Therapy

Ocugen Inc Registers Direct Offering of $20 Million in Common Stock and Warrants

Ocugen signs $20 million securities purchase agreement with Janus Henderson

Ocugen released FY2025 Q2 earnings on August 1 Pre-Market EST, actual revenue USD 1.373 M (forecast USD 350 K), actual EPS USD -0.0504 (forecast USD -0.0566)

Ocugen released FY2025 Semi-Annual earnings on August 1 Pre-Market EST, actual revenue USD 2.854 M, actual EPS USD -0.103

Ocugen Exceeds Earnings Expectations and Announces Reverse Merger

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Ocugen, Inc.'s (OCGN.US) Q4 2024 earnings conference call

OCGN

IBBQ

LABU

SBIO

Ocugen Inc. (OCGN) shares fell 2.99% to $1.30 on Tuesday, marking the fourth consecutive day of losses. The stock is now 52.29% below its 52-week high of $2.73 reached on March 17. The broader market also declined, with the S&P 500 down 0.67% and the Dow Jones down 0.65%. Trading volume was 5.5 million, below the 50-day average of 9.4 million.

MarketWatch Automated

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

ALPS Medical Breakthrough

iShares Biotechnology ETF

S&P 500

Dow Jones Industrial Average

Ocugen Inc. Stock Falls Tuesday, Underperforms Market

Ocugen Inc. (OCGN) shares fell 4.79% to $1.39 on Friday, marking the second consecutive day of losses amid a broader market decline, with the S&P 500 down 1.24%. The stock is currently 48.99% below its 52-week high of $2.73 reached on March 17. Trading volume was 4.8 million, significantly below the 50-day average of 9.4 million.

Direxion S&P Biotech Bear 3X

Factset Research

Ocugen Inc. Stock Falls Friday, Underperforms Market

Ocugen has raised $130 million through a private offering of 6.75% Convertible Senior Notes due 2034. The offering included $115 million initially and an additional $15 million from an over-allotment option. The net proceeds of approximately $112.6 million will be used to repay a loan and support corporate purposes, extending the company's cash runway into 2028. The notes may be converted into cash or stock, potentially diluting existing shareholders. Analysts rate OCGN stock as a Buy with a $10.00 price target, though concerns about financial performance and execution risks remain.

Tip Ranks

Ocugen Raises $130 Million Through Convertible Notes Offering

Ocugen to Participate in Upcoming May Scientific and Investor Conferences | OCGN Stock News

StockTitan

Ocugen to Participate in Upcoming May Scientific and Investor Conferences | OCGN Stock News

Shares of Ocugen Inc. (OCGN) fell 1.99% to $1.48 on Monday, underperforming the overall market, which saw the S&P 500 and Dow Jones both rise by 0.19%. The stock is currently 45.69% below its 52-week high of $2.73 reached on March 17. Trading volume was 9.6 million, slightly below the 50-day average of 9.7 million.

Ocugen Inc. Stock Falls Monday, Underperforms Market

Shares of Ocugen Inc. (OCGN) rose 4.86% to $1.51 on Friday, outperforming the market as the S&P 500 increased by 0.84% and the Dow Jones by 0.02%. This rise ended a three-day losing streak, although the stock remains 44.59% below its 52-week high of $2.73 reached on March 17. Trading volume was 10.1 million, surpassing the 50-day average of 9.7 million.

Ocugen Inc. Stock Rises Friday, Outperforms Market

Shares of Ocugen Inc. (OCGN) fell 1.03% to $1.44 on Thursday, marking the third consecutive day of losses amid a broader market decline, with the S&P 500 down 0.38% and the Dow Jones down 0.63%. The stock is currently 47.16% below its 52-week high of $2.73 reached on March 17. Trading volume was 13.6 million, surpassing the 50-day average of 9.6 million.

Bosera S&P 500 ETF

Guotai S&P 500 ETF(QDII)

SPDR S&P 500

iShares Core S&P 500

VG S&P 500

Nomura Holdings, Inc.

SPDR Djia

News

News Corporation Shs B Chess Depository Interests repr 1 Sh

News Corporation Shs A Chess Depository Interests repr 1 Sh

Ocugen Inc. Stock Falls Thursday, Underperforms Market

Ocugen, Inc. has completed a private offering of $115 million in 6.75% Convertible Senior Notes due 2034, generating approximately $99.5 million in net proceeds. The funds will be used to repay an existing loan and for general corporate purposes. The notes are convertible into common stock under certain conditions and include investor protections. Analysts rate OCGN stock as a Buy with a $7.00 price target, while AI analysis suggests a Neutral outlook due to high financial risk and ongoing cash burn.

Nasdaq

Ocugen Raises Capital Through Convertible Senior Notes Offering

Shares of Ocugen Inc. (OCGN) fell 2.35% to $1.46 on Wednesday, underperforming the market as the S&P 500 rose 1.46% and the Dow Jones increased by 1.24%. This marks the second consecutive day of losses for Ocugen, which is now 46.61% below its 52-week high of $2.73 reached on March 17. Trading volume was 15.4 million, surpassing the 50-day average of 9.4 million.

Ocugen Inc. Stock Falls Wednesday, Underperforms Market

Ocugen(OCGN.US)

Ocugen Inc. Stock Falls Tuesday, Underperforms Market

Ocugen Inc. Stock Falls Friday, Underperforms Market

Ocugen Raises $130 Million Through Convertible Notes Offering

Ocugen to Participate in Upcoming May Scientific and Investor Conferences | OCGN Stock News

Ocugen Inc. Stock Falls Monday, Underperforms Market

Ocugen Inc. Stock Rises Friday, Outperforms Market

Ocugen Inc. Stock Falls Thursday, Underperforms Market

Ocugen Raises Capital Through Convertible Senior Notes Offering

Ocugen Inc. Stock Falls Wednesday, Underperforms Market